Trump Taps Heidi Overton as FDA Commissioner in Major Health Pick

President Donald Trump has chosen Dr. Heidi Overton, a physician and top White House domestic policy official, to lead the Food and Drug Administration. The pick, confirmed by senior administration officials late Tuesday, ends months of speculation about who would take charge of the agency after a turbulent year. Overton is a leading voice behind the administration's Make America Healthy Again agenda, signaling that commonsense medicine is about to get a seat at the agency's top table.

The decision continues a long tradition of placing a medical doctor at the helm of the FDA. If confirmed by the Senate, Overton would take over an agency that has been running under acting leadership since May, when former commissioner Marty Makary stepped down.

A Physician and MAHA Insider Takes the Helm

Overton currently serves as deputy director of the White House Domestic Policy Council and has worked as deputy assistant to the president for health policy since Trump returned to office. She was one of several candidates the White House weighed for weeks before settling on the pick.

Before joining the administration, Overton built her reputation at the America First Policy Institute, the think tank that has become a talent pipeline for the Trump administration. Her background as a trained physician and her role shaping health policy from inside the West Wing make her a natural fit for an agency that sits at the center of American medicine.

Her advocacy for the Make America Healthy Again initiative is widely seen as the driving force behind the selection. The movement has pushed to reexamine the food supply, chronic disease, and the influence of money in medicine, and Overton's arrival at the FDA would put those priorities at the center of federal health regulation.

What She Inherits at FDA

Overton would step into an agency in the middle of a transformation. The FDA has shed more than 3,000 employees over the past year, including leaders of several divisions, as part of the administration's drive to cut waste and streamline federal bureaucracy.

Acting chief Kyle Diamantas has held the agency together since Makary's departure in May. The pending nomination gives the administration a chance to put its own permanent stamp on the agency, which has been under pressure to rebuild confidence among industry and public health groups alike.

The pick is part of a broader reshuffle. Other top FDA positions still lack permanent leadership, and officials say more decisions will likely follow quickly behind Overton's nomination.

The Road to Confirmation

Overton was one of three finalists for the post, alongside oncologist Jeffrey Vacirca and Pentagon health official Stephen Ferrara. The White House ultimately settled on Overton, a choice that keeps the decades-old tradition of a physician leading the FDA intact.

The nomination now heads to the Senate, where Overton will face confirmation hearings. Given the administration's focus on health policy and the Make America Healthy Again agenda, the pick is expected to draw strong support from conservative health advocates who have long called for a shakeup at the agency.

What to Watch Next

The Overton nomination is the clearest signal yet that the administration intends to follow through on its health promises with personnel who share the vision. Her confirmation would put a White House insider with deep policy experience in charge of the agency that regulates everything from prescription drugs to the nation's food supply.

Watch for the formal nomination announcement, the Senate confirmation schedule, and the expected wave of additional FDA appointments in the weeks ahead. If confirmed, Overton would inherit one of the most consequential regulatory jobs in government -- and a mandate to match the agency's rules with the administration's health agenda.